Advertisement
Review Article| Volume 50, ISSUE 1, P79-88, March 2023

Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Steegers E.A.
        • Von Dadelszen P.
        • Duvekot J.J.
        • et al.
        Pre-eclampsia.
        Lancet. 2010; 376: 631-644
        • Espinoza J.
        • Vidaeff A.
        • Pettker C.M.
        • et al.
        ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia.
        Obstet Gynecol. 2019; 133: e1-e25
        • Ronsmans C.
        • Graham W.J.
        Maternal mortality: who, when, where, and why.
        Lancet. 2006; 368: 1189-1200
        • Khan K.S.
        • Wojdyla D.
        • Say L.
        • et al.
        WHO analysis of causes of maternal death: a systematic review.
        Lancet. 2006; 367: 1066-1074
        • Duley L.
        The Global Impact of Pre-eclampsia and Eclampsia.
        Semin Perinatol. 2009; 33: 130-137
        • MacKay A.P.
        • Berg C.J.
        • Duran C.
        • et al.
        An assessment of pregnancy-related mortality in the United States.
        Paediatr Perinat Epidemiol. 2005; 19: 206-214
        • Wang A.
        • Rana S.
        • Karumanchi S.A.
        Preeclampsia: the role of angiogenic factors in its pathogenesis.
        Physiology (Bethesda). 2009; 24: 147-158
        • Stevens W.
        • Shih T.
        • Incerti D.
        • et al.
        Short-term costs of preeclampsia to the United States health care system.
        Am J Obstet Gynecol. 2017; 217: 237-248 e216
        • Centers for Disease Control and Prevention
        Meeting the challenges of measuring and preventing maternal mortality in the United States. Public Health Grand Rounds.
        (Available at:) (Accessed June 6, 2022)
        • Howell E.A.
        Reducing disparities in severe maternal morbidity and mortality.
        Clin Obstet Gynecol. 2018; 61: 387-399
        • Cunningham F.
        • Leveno K.
        • Bloom F.
        • et al.
        Williams obstetrics.
        24th edition. McGraw-Hill Education, New York2014
        • Roberts J.M.
        • Hubel C.A.
        The two stage model of preeclampsia: variations on the theme.
        Placenta. 2009; 30: S32-S37
        • Sargent I.L.
        • Germain S.J.
        • Sacks G.P.
        • et al.
        Trophoblast deportation and the maternal inflammatory response in pre-eclampsia.
        J Reprod Immunol. 2003; 59: 153-160
        • Walsh S.W.
        Eicosanoids in preeclampsia.
        Prostaglandins Leukot Essent Fatty Acids. 2004; 70: 223-232
        • Walsh S.W.
        Preeclampsia: an imbalance in placental prostacyclin and thromboxane production.
        Am J Obstet Gynecol. 1985; 152: 335-340
        • Moncada S.
        • Vane J.R.
        Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel Walls.
        N Engl J Med. 1979; 300: 1142-1147
        • Mills J.L.
        • DerSimonian R.
        • Raymond E.
        • et al.
        Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: A multicenter prospective study.
        J Am Med Assoc. 1999; 282: 356-362
      1. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. In: Seminars in Nephrology. ; 2004.

        • Zeisler H.
        • Llurba E.
        • Chantraine F.
        • et al.
        Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.
        N Engl J Med. 2016; 374: 13-22
        • Herraiz I.
        • Llurba E.
        • Verlohren S.
        • et al.
        Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/PlGF Ratio in Singleton Pregnancies.
        Fetal Diagn Ther. 2018; 43: 81-89
        • Levine R.J.
        • Lam C.
        • Qian C.
        • et al.
        Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
        N Engl J Med. 2006; 355: 992-1005
        • Roberts J.M.
        Pathophysiology of ischemic placental disease.
        Semin Perinatol. 2014; 38: 139-145
        • Atallah A.
        • Lecarpentier E.
        • Goffinet F.
        • et al.
        Aspirin for prevention of preeclampsia.
        Drugs. 2017; 77: 1819-1831
        • Vane J.R.
        Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
        Nat New Biol. 1971; 231: 232-235
        • Majed B.H.
        • Khalil R.A.
        Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn.
        Pharmacol Rev. 2012; 64: 540-582
        • Paul B.Z.S.
        • Jin J.
        • Kunapuli S.P.
        Molecular mechanism of thromboxane A2-induced platelet aggregation.
        J Biol Chem. 1999; 274: 29108-29114
        • Patrick J.
        • Dillaha L.
        • Armas D.
        • et al.
        A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
        Postgrad Med. 2015; 127: 573-580
        • Lin L.
        • Li G.
        • Zhang W.
        • et al.
        Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells.
        J Cell Physiol. 2019; 234: 18928-18941
        • Li C.
        • Raikwar N.S.
        • Santillan M.K.
        • et al.
        Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.
        Placenta. 2015; 36: 446-453
        • Patrono C.
        • Ciabattoni G.
        • Pinca E.
        • et al.
        Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.
        Thromb Res. 1980; 17: 317-327
        • Gonzalez-Brown V.M.
        • Ma'ayeh M.
        • Kniss D.A.
        • et al.
        Low-dose aspirin increases 15-epi-lipoxins A4 in pregnancies at high-risk for developing preeclampsia.
        Pregnancy Hypertens. 2021; 26: 75-78
        • Crandon A.J.
        • Isherwood D.M.
        Effect of aspirin on incidence of preeclampsia.
        Lancet. 1979; 1: 1356
        • Caritis S.
        • Sibai B.
        • Hauth J.
        • et al.
        Low-dose aspirin to prevent preeclampsia in women at high risk.
        N Engl J Med. 1998; 338: 701-705
        • CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group
        CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women.
        Lancet. 1994; 343: 619-629
        • Sibai B.M.
        • Caritis S.N.
        • Thom E.
        • et al.
        Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women.
        N Engl J Med. 1993; 329: 1213-1218
        • Roberge S.
        • Bujold E.
        • Nicolaides K.H.
        Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.
        Am J Obstet Gynecol. 2018; 218: 287-293.e1
        • Meher S.
        • Duley L.
        • Hunter K.
        • et al.
        Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis.
        Am J Obstet Gynecol. 2017; 216: 121-128.e2
        • Roberge S.
        • Nicolaides K.
        • Demers S.
        • et al.
        The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
        Am J Obstet Gynecol. 2017; 216: 110-120.e6
        • Rolnik D.L.
        • Wright D.
        • Poon L.C.Y.
        • et al.
        ASPRE trial: performance of screening for preterm pre-eclampsia.
        Ultrasound Obstet Gynecol. 2017; 50: 492-495
        • Rolnik D.L.
        • O’Gorman N.
        • Roberge S.
        • et al.
        Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.
        Ultrasound Obstet Gynecol. 2017; 50: 551-556
        • Poon L.C.Y.
        • Kametas N.A.
        • Maiz N.
        • et al.
        First-trimester prediction of hypertensive disorders in pregnancy.
        Hypertension. 2009; 53: 812-818
        • Committee Opinion No. 638
        American college of obstetricians and gynecologists. first-trimester risk assessment for early-onset preeclampsia.
        Obstet Gynecol. 2015; 126: e25-e27
        • Rolnik D.L.
        • Wright D.
        • Poon L.
        • et al.
        Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia.
        N Engl J Med. 2017; 377: 613-622
        • LeFevre M.L.
        Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2014; 161: 819-826
        • ACOG Practice Bulletin No. 202
        Gestational hypertension and preeclampsia.
        Obstet Gynecol. 2019; 133: 1
        • Henderson J.T.
        • Vesco K.K.
        • Senger C.A.
        • et al.
        Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the us preventive services task force.
        JAMA. 2021; 326: 1192-1206
        • Ayala N.K.
        • Rouse D.J.
        A nudge toward universal aspirin for preeclampsia prevention.
        Obstet Gynecol. 2019; 133: 725-728
        • Werner E.F.
        • Hauspurg A.K.
        • Rouse D.J.
        A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States.
        Obstet Gynecol. 2015; 126: 1242-1250
        • Subtil D.
        • Goeusse P.
        • Puech F.
        • et al.
        Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1).
        BJOG. 2003; 110: 475-484
        • Rotchell Y.E.
        • Cruickshank J.K.
        • Gay M.P.
        • et al.
        Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.
        Br J Obstet Gynaecol. 1998; 105: 286-292
        • Henderson J.T.
        • Whitlock E.P.
        • O’Connor E.
        • et al.
        Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task force.
        Ann Intern Med. 2014; 160: 695-703
        • Duley L.
        • Henderson-Smart D.J.
        • Meher S.
        • et al.
        Antiplatelet agents for preventing pre-eclampsia and its complications.
        Cochrane Database Syst Rev. 2007; 2: CD004659
        • Roberge S.
        • Bujold E.
        • Nicolaides K.H.
        Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage.
        Am J Obstet Gynecol. 2018; 218: 483-489
        • Horlocker T.T.
        • Vandermeuelen E.
        • Kopp S.L.
        • et al.
        Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: american society of regional anesthesia and pain medicine evidence-based guidelines (4th edition).
        Reg Anesth Pain Med. 2018; 43: 263-309
        • Caniggia I.
        • Post M.
        • Ermini L.
        Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia.
        Curr Mol Pharmacol. 2016; 10: 152-160
        • Istvan E.S.
        • Deisenhofer J.
        Structural mechanism for statin inhibition of HMG-CoA reductase.
        Science. 2001; 292: 1160-1164
        • Esteve-Valverde E.
        • Ferrer-Oliveras R.
        • Gil-Aliberas N.
        • et al.
        Pravastatin for preventing and treating preeclampsia: a systematic review.
        Obstet Gynecol Surv. 2018; 73: 40-55
        • Nanovskaya T.N.
        • Patrikeeva S.L.
        • Paul J.
        • et al.
        Transplacental transfer and distribution of pravastatin.
        Am J Obstet Gynecol. 2013; 209: e1-e5
        • Kumasawa K.
        • Ikawa M.
        • Kidoya H.
        • et al.
        Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.
        Proc Natl Acad Sci. 2010; 108: 1451-1455
        • Costantine M.M.
        • Tamayo E.
        • Lu F.
        • et al.
        Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia.
        Obstet Gynecol. 2010; 116: 114-120
        • Girardi G.
        Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies.
        J Reprod Immunol. 2017; 124: 15-20
        • Bauer A.J.
        • Banek C.T.
        • Needham K.
        • et al.
        Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension.
        Hypertension. 2013; 61: 1103-1110
        • Lefkou E.
        • Mamopoulos A.
        • Fragakis N.
        • et al.
        Clinical Improvement and Successful Pregnancy in a Preeclamptic Patient With Antiphospholipid Syndrome Treated With Pravastatin.
        Hypertension. 2014; 63: e118-e119
        • Lefkou E.
        • Mamopoulos A.
        • Dagklis T.
        • et al.
        Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.
        J Clin Invest. 2016; 126: 2933-2940
        • Brownfoot F.C.
        • Tong S.
        • Hannan N.J.
        • et al.
        Effects of Pravastatin on Human Placenta, Endothelium, and Women with Severe Preeclampsia.
        Hypertension. 2015; 66: 687-697
        • Costantine M.M.
        • Cleary K.
        • Hebert M.F.
        • et al.
        Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial.
        Am J Obstet Gynecol. 2016; 214: e1-e17
        • Kupferminc M.J.
        • Kliger C.
        • Rimon E.
        • et al.
        Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
        J Matern Fetal Neonatal Med. 2021; : 1-7https://doi.org/10.1080/14767058.2021.1940940
        • Akbar M.I.A.
        • Azis M.A.
        • Riu D.S.
        • et al.
        INOVASIA study: a multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high-risk patients.
        Am J Perinatol. 2022; ([published online ahead of print, 2022 Jun 6])https://doi.org/10.1055/a-1798-1925
        • Döbert M.
        • Varouxaki A.N.
        • Mu A.C.
        • et al.
        Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.
        Circulation. 2021; 144: 670-679
        • Mach F.
        • Ray K.K.
        • Wiklund O.
        • et al.
        Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
        Eur Heart J. 2018; 39: 2526-2539
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • et al.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Karalis D.G.
        • Hill A.N.
        • Clifton S.
        • et al.
        The risks of statin use in pregnancy: A systematic review.
        J Clin Lipidol. 2016; 10: 1081-1090
        • Bateman B.T.
        • Hernandez-Diaz S.
        • Fischer M.A.
        • et al.
        Statins and congenital malformations: cohort study.
        BMJ. 2015; 350: h1035
        • US Food and Drug Administration
        FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins.
        (Available at:) (Accessed June 29, 2022)